From October 1, 2021 to December 31, 2021, the company has repurchased 0 shares, representing 0% for CNY 0 million. With this, the company has completed the repurchase of 4,139,200 shares, representing 0.67% for CNY 50.95 million under the buyback announced on March 15, 2021.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
4.46 CNY | +4.69% | -8.04% | -30.31% |
20/05 | Wanbangde Pharmaceutical Holding Group Co., Ltd. Approves Dividend for the Year 2023 | CI |
08/05 | US FDA Gives Rare Pediatric Disease Drug Designation to Wanbangde Pharmaceutical's Huperzine A | MT |
1st Jan change | Capi. | |
---|---|---|
-30.31% | 360M | |
+19.64% | 42.33B | |
+21.25% | 22.47B | |
+18.92% | 15.25B | |
+53.19% | 12.6B | |
-0.05% | 6.79B | |
-11.11% | 6.71B | |
-8.87% | 5.73B | |
+14.27% | 5.47B | |
+6.91% | 4.78B |
- Stock Market
- Equities
- 002082 Stock
- News Wanbangde Pharmaceutical Holding Group Co., Ltd.
- Tranche Update on Wanbangde Pharmaceutical Holding Group Co., Ltd.'s Equity Buyback Plan announced on March 15, 2021.